Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111958037> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W3111958037 endingPage "iii419" @default.
- W3111958037 startingPage "iii419" @default.
- W3111958037 abstract "Abstract INTRODUCTION Vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), and c-KIT represent clinically and/or preclinically validated molecular targets in vestibular schwannomas. We conducted a single institution, prospective, open-label, two-stage phase II study (ClinicalTrials.gov identifier NCT02129647) to estimate the response rate to axitinib, an oral multi-receptor tyrosine kinase inhibitor targeting VEGFR, PDGFR and c-KIT, in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannomas (VS). METHODS NF2 patients older than 5 years with at least one volumetrically measurable, progressive VS were eligible. The primary endpoint was to estimate the objective volumetric response rates to axitinib. Axitinib was given continuously in 28-day cycles for up to of 12 cycles. Response was assessed every 3 months with MRI using 3-D volumetric tumor analysis and audiograms. Volumetric response and progression were defined as ≥20% decrease or increase in VS volume, respectively. RESULTS Twelve eligible patients (ages: 14–56 years) were enrolled on this study. Seven of twelve patients completed 12 cycles (range: 2 to 12 cycles). We observed two imaging and three hearing responses. Best volumetric response was -53.9% after nine months on axitinib. All patients experienced drug-related toxicities, the most common adverse events were diarrhea, hematuria and skin toxicity, not exceeding grade 2 and hypertension, not exceeding grade 3. CONCLUSIONS While axitinib has modest anti-tumor activity in NF2 patients, it is more toxic and appears to be less effective compared to bevacizumab. Based on these findings, further clinical development of axitinib for this indication does not appear warranted." @default.
- W3111958037 created "2020-12-21" @default.
- W3111958037 creator A5007528270 @default.
- W3111958037 creator A5011528218 @default.
- W3111958037 creator A5020881740 @default.
- W3111958037 creator A5028204560 @default.
- W3111958037 creator A5038695132 @default.
- W3111958037 creator A5048365483 @default.
- W3111958037 creator A5049751913 @default.
- W3111958037 creator A5067419044 @default.
- W3111958037 creator A5083585208 @default.
- W3111958037 creator A5090555697 @default.
- W3111958037 date "2020-12-01" @default.
- W3111958037 modified "2023-10-16" @default.
- W3111958037 title "NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS" @default.
- W3111958037 doi "https://doi.org/10.1093/neuonc/noaa222.612" @default.
- W3111958037 hasPublicationYear "2020" @default.
- W3111958037 type Work @default.
- W3111958037 sameAs 3111958037 @default.
- W3111958037 citedByCount "4" @default.
- W3111958037 countsByYear W31119580372022 @default.
- W3111958037 countsByYear W31119580372023 @default.
- W3111958037 crossrefType "journal-article" @default.
- W3111958037 hasAuthorship W3111958037A5007528270 @default.
- W3111958037 hasAuthorship W3111958037A5011528218 @default.
- W3111958037 hasAuthorship W3111958037A5020881740 @default.
- W3111958037 hasAuthorship W3111958037A5028204560 @default.
- W3111958037 hasAuthorship W3111958037A5038695132 @default.
- W3111958037 hasAuthorship W3111958037A5048365483 @default.
- W3111958037 hasAuthorship W3111958037A5049751913 @default.
- W3111958037 hasAuthorship W3111958037A5067419044 @default.
- W3111958037 hasAuthorship W3111958037A5083585208 @default.
- W3111958037 hasAuthorship W3111958037A5090555697 @default.
- W3111958037 hasBestOaLocation W31119580371 @default.
- W3111958037 hasConcept C121608353 @default.
- W3111958037 hasConcept C126322002 @default.
- W3111958037 hasConcept C126894567 @default.
- W3111958037 hasConcept C141071460 @default.
- W3111958037 hasConcept C143998085 @default.
- W3111958037 hasConcept C197934379 @default.
- W3111958037 hasConcept C203092338 @default.
- W3111958037 hasConcept C2776539811 @default.
- W3111958037 hasConcept C2778679214 @default.
- W3111958037 hasConcept C2778820342 @default.
- W3111958037 hasConcept C2779490328 @default.
- W3111958037 hasConcept C2781447767 @default.
- W3111958037 hasConcept C2909220140 @default.
- W3111958037 hasConcept C31760486 @default.
- W3111958037 hasConcept C535046627 @default.
- W3111958037 hasConcept C71924100 @default.
- W3111958037 hasConcept C90924648 @default.
- W3111958037 hasConceptScore W3111958037C121608353 @default.
- W3111958037 hasConceptScore W3111958037C126322002 @default.
- W3111958037 hasConceptScore W3111958037C126894567 @default.
- W3111958037 hasConceptScore W3111958037C141071460 @default.
- W3111958037 hasConceptScore W3111958037C143998085 @default.
- W3111958037 hasConceptScore W3111958037C197934379 @default.
- W3111958037 hasConceptScore W3111958037C203092338 @default.
- W3111958037 hasConceptScore W3111958037C2776539811 @default.
- W3111958037 hasConceptScore W3111958037C2778679214 @default.
- W3111958037 hasConceptScore W3111958037C2778820342 @default.
- W3111958037 hasConceptScore W3111958037C2779490328 @default.
- W3111958037 hasConceptScore W3111958037C2781447767 @default.
- W3111958037 hasConceptScore W3111958037C2909220140 @default.
- W3111958037 hasConceptScore W3111958037C31760486 @default.
- W3111958037 hasConceptScore W3111958037C535046627 @default.
- W3111958037 hasConceptScore W3111958037C71924100 @default.
- W3111958037 hasConceptScore W3111958037C90924648 @default.
- W3111958037 hasIssue "Supplement_3" @default.
- W3111958037 hasLocation W31119580371 @default.
- W3111958037 hasLocation W31119580372 @default.
- W3111958037 hasOpenAccess W3111958037 @default.
- W3111958037 hasPrimaryLocation W31119580371 @default.
- W3111958037 hasRelatedWork W2066384293 @default.
- W3111958037 hasRelatedWork W2516277182 @default.
- W3111958037 hasRelatedWork W2588439524 @default.
- W3111958037 hasRelatedWork W2806950290 @default.
- W3111958037 hasRelatedWork W2886193299 @default.
- W3111958037 hasRelatedWork W2908181257 @default.
- W3111958037 hasRelatedWork W3089163820 @default.
- W3111958037 hasRelatedWork W3111161573 @default.
- W3111958037 hasRelatedWork W3111958037 @default.
- W3111958037 hasRelatedWork W4377819842 @default.
- W3111958037 hasVolume "22" @default.
- W3111958037 isParatext "false" @default.
- W3111958037 isRetracted "false" @default.
- W3111958037 magId "3111958037" @default.
- W3111958037 workType "article" @default.